BDTX — Black Diamond Therapeutics Share News
0.000.00%
Last trade - 00:00- $100.28m
- -$17.98m
- $70.00m
Black Diamond Therapeutics soars on positive data from early-stage lung cancer study
Brief: Black Diamond Therapeutics Says Update On Phase 1 Dose Escalation Data In GBM Cohort Anticipated In Q4 2023
Black Diamond Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Black Diamond Therapeutics Reports First Quarter 2023 Financial Results
Black Diamond Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview
Brief: Black Diamond Therapeutics Says Dose Expansion Cohorts For Bdtx-1535 Phase 1 Expected To Open In 2023
Brief: Black Diamond Therapeutics Says Size Of Board Got Reduced
Brief: Black Diamond Therapeutics Announces Changes To Board Of Directors
Brief: Black Diamond Therapeutics Announces Spinout Of Launchpad Therapeutics
Brief: Black Diamond Therapeutics Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing
Black Diamond Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Black Diamond Therapeutics Reports Third Quarter Results
Brief: Black Diamond Therapeutics Reports Quarterly Loss Of $0.60 Per Share
Black Diamond Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Black Diamond Therapeutics Presents Preclinical Data On Bdtx-1535 And Bdtx-4933
Black Diamond Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. RESEARCH ROUNDUP- Axon Enterprise, Berkeley Lights, Minerva Surgical
Brief: Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results
Black Diamond Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview